More intensive therapy has a better effect for frail parents with multiple myeloma

Although randomized controlled trial data suggest that the more intensive triplet bortezomib-lenalidomide-dexamethasone (VRd) is superior to the less intensive doublet lenalidomide-dexamethasone (Rd) in patients newly diagnosed with multiple myeloma (MM), guidelines have historically recommended Rd...

Descripción completa

Detalles Bibliográficos
Autores principales: DuMontier, Clark, La, Jennifer, Bihn, John, Corrigan, June, Yildirim, Cenk, Dharne, Mayuri, Hassan, Hamza, Yellapragada, Sarvari, Abel, Gregory A., Gaziano, J Michael, Do, Nhan V., Brophy, Mary, Kim, Dae H., Munshi, Nikhil C., Fillmore, Nathanael R., Driver, Jane A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589796/
https://www.ncbi.nlm.nih.gov/pubmed/37582048
http://dx.doi.org/10.1182/bloodadvances.2023011019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589796/
https://www.ncbi.nlm.nih.gov/pubmed/37582048
http://dx.doi.org/10.1182/bloodadvances.2023011019

Ejemplares similares